Pleural effusion formation in the course of myeloma. Comert M etal. Arch Bronconeumol. 2015 Jan 22. pii: S0300-2896(14)00242-7. doi: 10.1016/j.arbres.2014.05.009. [Epub ahead of print]. Diagnosis of monoclonal gammopathy of renal significance. Bridoux F et al. Kidney Int. 2015 Jan 21. doi: 10.1038/ki.2014.408. [Epub ahead of print]. Paralytic ileus following “subcutaneous bortezomib” therapy: focus on the clinical emergency-report of two cases. Mele…
An open label phase I/II study of cyclophosphamide, bortezomib, pegylated liposomal doxorubicin and dexamethasone in newly diagnosed myeloma. Nishihori T et al. Eur J Haematol. 2015 Jan 20. doi: 10.1111/ejh.12509. [Epub ahead of print]. A Phase II trial of weekly bortezomib and dexamethasone in veterans with newly diagnosed multiple myelomanot eligible for or who deferred autologous stem cell transplantation.…
Heavy/Light Chain Assay for Monitoring IgA Multiple Myeloma: Digging Out the IgA from the β Region. Calderon B et al. Clin Chem. 2014 Dec 10. pii: clinchem.2014.234757. [Epub ahead of print]. Dysregulated class I histone deacetylases are indicators of poor prognosis in multiple myeloma. Mithraprabhu S et al. Epigenetics. 2014 Dec 6:0. [Epub ahead of print]. Calorimetric markers of bence jones and nonsecretory multiple…
Smoldering multiple myeloma: special considerations surrounding treatment on versus off clinical trials. Manasanch EE et al. Haematologica. 2014 Dec;99(12):1769-71. doi: 10.3324/haematol.2014.107516. Disseminated sclerotic bone lesions with normal 18F-FDG uptake in POEMS syndrome. Shi X et al. Leuk Lymphoma. 2014 Dec 2:1-9. [Epub ahead of print]. Monoclonal gammopathy of renal significance with light-chain deposition disease diagnosed postrenal transplant: a diagnostic and therapeutic challenge.…
Carfilzomib, Lenalidomide, and Dexamethasone for Relapsed Multiple Myeloma. Stewart AK et al. N Engl J Med. 2014 Dec 6. [Epub ahead of print]. Phase I/II study exploring ImMucin, a pan-major histocompatibility complex, anti-MUC1 signal peptide vaccine, inmultiple myeloma patients. Carmon L et al. Br J Haematol. 2014 Dec 11. doi: 10.1111/bjh.13245. [Epub ahead of print]. The potential role of PD0332991 (Palbociclib) in the…
Curcumin induces cell death of the main molecular myeloma subtypes, particularly the poor prognosis subgroups. Gomez-Bougie P et al. Cancer Biol Ther. 2014 Dec 17:0. [Epub ahead of print]. Daratumumab-mediated lysis of primary multiple myeloma cells is enhanced in combination with the human anti-KIR antibody IPH2102 and lenalidomide. Nijhof IS et al. Haematologica. 2014 Dec 15. pii: haematol.2014.117531. [Epub ahead of print]. Doxorubicin Overcomes Resistance…
Pain reduction after percutaneous vertebroplasty for myeloma-associated vertebral fractures.
Simony A et al. Dan Med J. 2014 Dec;61(12):A4945.
Bone-targeted therapies for cancer patients and bone cell biology: where do we stand?
Berenson JR et al. Curr Opin Support Palliat Care. 2014 Dec;8(4):405-6. doi: 10.1097/SPC.0000000000000104.
The Role Of P2X Receptors In Bone Biology. Jorgensen NR et al. Curr Med Chem. 2014 Dec 14. [Epub ahead of print]. A joined role of canopy and reversal cells in bone remodeling – Lessons from glucocorticoid-induced osteoporosis. Jensen PR et al. Bone. 2014 Dec 10. pii: S8756-3282(14)00456-6. doi: 10.1016/j.bone.2014.12.004. [Epub ahead of print]. Multiple myeloma and chronic leukaemias in 2014: Improved…
Bortezomib-induced acute pancreatitis: Case report and review of the literature. Talamo G et al. J Oncol Pharm Pract. 2014 Dec 15. pii: 1078155214563813. [Epub ahead of print]. Risks and burden of viral respiratory tract infections in patients with multiple myeloma in the era of immunomodulatory drugs and bortezomib: experience at an Australian Cancer Hospital. Teh BW et al. Support Care Cancer. 2014 Dec…
Efficacy and safety of bortezomib-based retreatment at the first relapse in multiple myeloma patients: a retrospective study.
Oriol A et al. Hematology. 2014 Dec 10. [Epub ahead of print]